William Suh, MD
Cardiovascular Disease · Corona, CANPI 1740200351
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $43,688 of the $62,127 with a category attached, or 70.3%. Edwards Lifesciences accounts for 91.1% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2020 at $36,672 and has fallen 86.5% since, to $4,952 in 2025. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 384 payments — averaging $161.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$57K
- Abbott$946
- Abiomed$602
- Shockwave Medical, Inc$541
- Amgen$468
- Medtronic$405
- plus $3K from 28 others
Across 13 payments — averaging $5632.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cardiovascular Systems Inc.$73K
What the payments were for
- Consulting fees$43,68870%
- Speaking & faculty fees$8,50014%
- Travel & lodging$3451%
- Food & beverage$9,59515%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 145 | $56,607 |
| Abbott | 36 | $946 |
| Abiomed | 35 | $602 |
| Shockwave Medical, Inc | 2 | $541 |
| Amgen | 31 | $468 |
| Medtronic | 12 | $405 |
| Amarin Pharma, Inc. | 29 | $354 |
| Boston Scientific | 4 | $275 |
| Novartis | 21 | $273 |
| Johnson & Johnson(2 entities) | 5 | $221 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $159 |
| E.r. Squibb & Sons, L.L.C. | 6 | $131 |
| Acist Medical Systems, Inc. | 3 | $129 |
| Pfizer | 4 | $111 |
| Merck | 4 | $106 |
| Bayer | 5 | $94 |
| Scpharmaceuticals Inc. | 4 | $94 |
| Biosense Webster, Inc. | 2 | $88 |
| AstraZeneca | 4 | $77 |
| Boehringer Ingelheim | 3 | $76 |
| Venclose Inc. | 1 | $55 |
| Cleerly, Inc. | 1 | $48 |
| Philips North America LLC | 2 | $47 |
| Redhill Biopharma Inc. | 2 | $28 |
| Irhythm Technologies, Inc. | 1 | $27 |
| Novo Nordisk | 1 | $23 |
| Avanos Medical | 1 | $22 |
| Exact Sciences | 1 | $21 |
| ZOLL Circulation Inc | 1 | $20 |
| Aspira Women's Health Inc | 1 | $18 |
| AbbVie | 1 | $18 |
| Siemens Medical Solutions USA, Inc. | 1 | $15 |
| Bard Peripheral Vascular, Inc. | 1 | $15 |
| GSK | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$62,127 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 46 | $43,206 |
| EntrestoSacubitril/Valsartan | 20 | $23,586 |
| FarxigaDapagliflozin Propanediol | 33 | $23,268 |
| XareltoRivaroxaban | 25 | $19,234 |
| Praluent PenAlirocumab | 12 | $13,397 |
| BrilintaTicagrelor | 19 | $12,669 |
| Ranolazine ErRanolazine | 29 | $3,464 |
| Valsartan | 38 | $2,337 |
| ClopidogrelClopidogrel Bisulfate | 85 | $1,332 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 141 | $1,191 |
| Metoprolol Succinate | 109 | $1,113 |
| Ezetimibe | 75 | $942 |
| Atorvastatin Calcium | 78 | $802 |
| Amlodipine Besylate | 143 | $787 |
| Rosuvastatin Calcium | 27 | $710 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $111 | $43,20646 claims |
| AstraZenecaFarxiga, Brilinta | $77 | $35,93752 claims |
| NovartisEntresto | $273 | $23,58620 claims |
| Johnson & JohnsonXarelto | $221 | $19,23425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Corona
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
- Wilber SuStanford$1.1M
- Thomas SmithSacramento$942K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.